Siegfried Announces Changes in its Board of Directors

At its last meeting, the Board of Directors of Siegfried Holding AG decided on proposals to be put forward at the Annual General Meeting (AGM) scheduled for 13 April 2022.

Reto A. Garzetti (1960), a member of the Board since 2011, will not stand for reelection at the 2022 AGM. He is Partner and Vice Chairman of SE Swiss Equities AG and a member of various boards.

Ulla Schmidt (1949) will also not stand for reelection at the next AGM. As a former German minister of health and a longstanding member of the German Parliament, Ulla Schmidt joined Siegfried’s Board of Directors in 2016.

Dr. Andreas Casutt (Chairman), Colin Bond, Prof. Dr. Wolfram Carius, Dr. Martin Schmid and Isabelle Welton will be proposed for reelection to the shareholders.

Furthermore, the Board of Directors decided to propose Dr. Alexandra Brand (1971) and Dr. Beat Walti (1968) for election.

Dr. Alexandra Brand, a German chemist, has held a senior management position with

Syngenta since 2015. She was Chief Sustainability Officer of the Syngenta Group until 2020 and subsequently managed Syngenta’s Crop Protection EAME division.

As a lawyer, Dr. Beat Walti is a partner of Wenger & Vieli AG, a Zurich-based law firm. He chairs the Foundation Board of the Ernst Göhner Stiftung and is, among other things, a member of the board of DSV A/S in Denmark. He was elected to the Swiss National Assembly in 2014 and is a member of its Commission for Economic Affairs and Taxes.

Siegfried Chairman Andreas Casutt: “As Board members, Reto A. Garzetti and Ulla Schmidt have played an important role in the dynamic development of our company in the past years, for which I am very grateful to them. I am extremely pleased to be able to propose two convincing personalities, Alexandra Brand and Beat Walti, for election to the Board. With her impressive professional experience in large corporations across many years, Alexandra Brand ideally complements our Board. As a lawyer, board member and politician, Beat Walti has a successful track record and will represent the Ernst Göhner Stiftung, a significant Siegfried shareholder, on the Board of Directors”.

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain (from 1.1.2021), France, Malta, the USA and China. In 2020, the company achieved sales of 845.1 million Swiss francs and employed on 31.12.2020 about 2’500 people at nine sites on three continents. Following the acquisition of two sites in Spain as per 01.01.2021, this number rose to approximately 3’500 employees. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.